Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine

Kim, E.S.; Chang, Jong Hee; Choi, Hyun Seok; Kim, J.; Lee, Seung Koo

doi:10.3174/ajnr.a2010

Cited by 43 publications

(38 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We primarily observed differences in peak enhancement values and increase of the initial enhancement, so that an effect of the charge differences between both contrast agents is probably negligible in this context. Differences were also found regarding the number of detected lesions during imaging of cerebral lesions of mammary carcinomas [20,27,28]. This was not reviewed in the current study.…”

Section: Figmentioning

confidence: 80%

Dynamic Contrast Enhanced MRI of the Prostate: Comparison of Gadobutrol and Gd-DTPA

Durmus

Vollnberg

Schwenke

et al. 2013

Fortschr Röntgenstr

View full text Add to dashboard Cite

Purpose: To evaluate the enhancement profile of the macrocyclic contrast medium (CM) gadobutrol in comparison to linear CM Gd-DTPA in DCE-MRI of the prostate. Materials and Methods: In total 53 patients with prostata cancer (PCa) were included, who received a radical prostatectomy after multiparametric MRI of the prostate including DCE-MRI. Using circular regions of interests normal peripheral zone (PZ) and PCa foci >?5?mm in diameter (42 and 34 foci in Gd-DTPA and gadobutrol group, respectively) were analysed in DCE-MRI. Enhancement curves (Type I, II and III) and pharmacokinetic parameters were analyzed qualitatively and quantitatively and compared using mixed linear models (two sided p-values

show abstract

Section: Figmentioning

confidence: 80%

Dynamic Contrast Enhanced MRI of the Prostate: Comparison of Gadobutrol and Gd-DTPA

Durmus

Vollnberg

Schwenke

et al. 2013

Fortschr Röntgenstr

View full text Add to dashboard Cite

show abstract

“…In similarly designed trials, gadobutrol has demonstrated superior performance, including enhanced lesion detection and conspicuity, compared with the 0.5-mol/L agents gadopentetate and gadoterate, administered at the same dose and by using the same field strength (1.5T), reflecting the high T1 shortening effect of gadobutrol (Fig 10). 94,98,105 Animal glioma models support the clinical observations of superior lesion enhancement with gadobutrol versus 0.5-mol/L agents, both at 1.5T and 3T. 77,106,107 Direct comparison of gadobutrol at 2 concentrations (with the same total dose) in volunteers demonstrated the benefits of the 1 mol/L over a 0.5-mol/L gadolinium concentration for CNS perfusion imaging, which is attributable to the sharper bolus peak and the increased first-pass gadolinium concentration related to a lower injection volume (Figs 11 and 12).…”

Section: Contrast Medium Choicementioning

confidence: 99%

“…[90][91][92] Numerous intraindividual trials have directly compared the imaging characteristics of contrast media in patients with primary CNS lesions or metastases. 91,[93][94][95][96][97][98][99][100][101][102][103][104] Among these trials, gadobenate dimeglumine has demonstrated superior lesion enhancement and diagnostic information compared with gadopentetate or gadodiamide, 99,100,102 which is attributed to the higher relaxivity of gadobenate. In similarly designed trials, gadobutrol has demonstrated superior performance, including enhanced lesion detection and conspicuity, compared with the 0.5-mol/L agents gadopentetate and gadoterate, administered at the same dose and by using the same field strength (1.5T), reflecting the high T1 shortening effect of gadobutrol (Fig 10).…”

Section: Contrast Medium Choicementioning

confidence: 99%

MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice

Essig¹,

Anzalone²,

Combs³

et al. 2011

AJNR Am J Neuroradiol

Self Cite

View full text Add to dashboard Cite

SUMMARY: MR imaging is the preferred technique for the diagnosis, treatment planning, and monitoring of patients with neoplastic CNS lesions. Conventional MR imaging, with gadolinium-based contrast enhancement, is increasingly combined with advanced, functional MR imaging techniques to offer morphologic, metabolic, and physiologic information. This article provides updated recommendations to neuroradiologists, neuro-oncologists, neurosurgeons, and radiation oncologists on the practical applications of MR imaging of neoplastic CNS lesions in adults, with particular focus on gliomas, based on a review of the clinical trial evidence and personal experiences shared at a recent international meeting of experts in neuroradiology, neuro-oncology, neurosurgery, and radio-oncology.ABBREVIATIONS: ADC ϭ apparent diffusion coefficient; CBV ϭ cerebral blood volume; CNS ϭ central nervous system; DCE ϭ dynamic contrast-enhanced; DSC ϭ dynamic susceptibility contrast; DTI ϭ diffusion tensor imaging; DWI ϭ diffusion-weighted imaging; FLAIR ϭ fluid-attenuated inversion recovery; FSE ϭ fast spin-echo; GFR ϭ glomerular filtration rate; GRE ϭ gradient recalled-echo; K trans ϭ volume transfer coefficient; MRS ϭ MR spectroscopy; PET ϭ positronemission tomography; PWI ϭ perfusion-weighted imaging; rCBV ϭ relative cerebral blood volume; TSE ϭ turbo spin-echo N eoplastic CNS lesions are a heterogeneous group of diseases with a variable outcome that reflects the precision of diagnosis and the delivery of optimal and specific treatment. CNS imaging has a pivotal role in directing management decisions.The goals and requirements for CNS imaging are multiple and include the establishment of a diagnosis and differential diagnosis, with accurate lesion grading for characterization of tumor biology. Imaging is an essential part of the decisionmaking process for therapy and later for planning of surgical or radiotherapeutic interventions. In the case of neurosurgery, neuroimaging can precisely define the location and accurately delineate the lesion and its relationship to eloquent gray-and white-matter structures, before intervention. In radiation therapy, imaging can define and demarcate margins for therapy planning. Imaging is mandatory after therapeutic intervention for monitoring disease and possible side effects.MR imaging is the standard technique for visualizing and characterizing neoplastic CNS lesions, with superior sensitivity compared with alternative modalities.1-4 Diagnosis and treatment planning are routinely based on conventional MR imaging, such as T2-weighted imaging, FLAIR, and T1 unenhanced FSE or GRE. Following contrast-enhanced T1-weighted imaging, sequences including 3D GRE or 2D TSE or FSE are used routinely for assessment of brain tumors. Through enhancing tissue relaxation, gadolinium-based contrast media improve the sensitivity and specificity of conventional and perfusion-weighted MR imaging examinations, with the capability to identify lesions not visible on unenhanced MR imaging and to provide additional information o...

show abstract

“…Due to its higher sensitivity, MRI has become the modality of choice for detection and delineation of brain tumors. Contrast-enhanced MRI is superior to non-enhanced MRI and conventional-dose contrast-enhanced computed tomography (CT) [11][12][13][14][15]. However, there are few reports on the usefulness of double-dose contrast-enhanced MRI in the diagnostic field [11,12,16].…”

Section: Introductionmentioning

confidence: 99%

Usefulness of Double Dose Contrast-enhanced Magnetic Resonance Imaging for Clear Delineation of Gross Tumor Volume in Stereotactic Radiotherapy Treatment Planning of Metastatic Brain Tumors: A Dose Comparison Study

Subedi

2013

Practical Radiation Oncology

View full text Add to dashboard Cite

The purpose of this study was to compare the size and clearness of gross tumor volumes (GTVs) of metastatic brain tumors on T1-weighted magnetic resonance images between a single dose contrast administration protocol and a double dose contrast administration protocol to determine the optimum dose of contrastenhancement for clear delineation of GTV in stereotactic radiotherapy (SRT). A total of 28 small metastatic brain tumors were evaluated in 13 patients by intra-individual comparison of GTV measurements using single dose and double dose contrast-enhanced thin-slice (1-mm) magnetic resonance imaging (MRI). All patients had confirmed histological types of primary tumors and had undergone hypo-fractionated SRT for metastatic brain tumors. The mean tumor diameter with single dose and double dose contrast-enhancement was 12.0 ± 1.1 mm and 13.2 ± 1.1 mm respectively (P < 0.001). The mean incremental ratio (MIR) obtained by comparing mean tumor diameters was 11.2 ± 0.02 %. The mean volume of GTV-1 (single dose contrastenhancement) and GTV-2 (double dose contrast-enhancement) was 1.38 ± 0.41 ml and 1.59 ± 0.45 ml respectively (P < 0.01). The MIR by comparing mean tumor volumes was 32.3 ± 0.4 %. The MIR of GTV-1 with < 1ml volume and GTV-1 with > 1ml volume was 41.8 ± 0.05 % and 12.4 ± 0.03 % respectively (P < 0.001). We conclude that double dose contrast-enhanced thin-slice MRI is a more useful technique than single dose contrast-enhanced thin-slice MRI, especially for clear delineation of GTVs of small metastatic brain tumors in treatment planning of highly precise SRT.

show abstract

Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine

Cited by 43 publications

References 23 publications

Dynamic Contrast Enhanced MRI of the Prostate: Comparison of Gadobutrol and Gd-DTPA

Dynamic Contrast Enhanced MRI of the Prostate: Comparison of Gadobutrol and Gd-DTPA

MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice

Usefulness of Double Dose Contrast-enhanced Magnetic Resonance Imaging for Clear Delineation of Gross Tumor Volume in Stereotactic Radiotherapy Treatment Planning of Metastatic Brain Tumors: A Dose Comparison Study

Contact Info

Product

Resources

About